Printer Friendly

STERLING WINTHROP AND BIOMIRA SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS

 STERLING WINTHROP AND BIOMIRA SIGN AGREEMENTS FOR THE DEVELOPMENT
 OF ANTIBODY-BASED CANCER PRODUCTS
 NEW YORK, Feb. 10 /PRNewswire/ -- Sterling Winthrop Inc. and Biomira Inc. today jointly announced that they have executed an option and license agreement and a research collaboration agreement involving the development and use of products incorporating antibodies developed against Biomira's synthetic carbohydrate antigens. Biomira had previously announced on Jan. 7, 1992 that an agreement in principle had been reached.
 These agreements provide Sterling Winthrop with an exclusive option to license on a worldwide (excluding Canada) basis existing antibodies and human antibodies derived from Biomira's program of immunization and sensitization of patients with synthetic carbohydrate antigens. This agreement does not affect Biomira's existing Active Specific Immunotherapy ("ASI") program (cancer "vaccine") in which Biomira has retained exclusive ownership.
 For existing Biomira antibodies, Sterling Winthrop's option to license extends to all radioisotopic therapeutic and non-radioisotopic imaging uses in human cancers. For human antibodies, Sterling Winthrop's option extends to all human cancer applications subject to certain limited rights retained by Biomira. Upon exercise of an option, Sterling Winthrop will be responsible for all further development costs associated with bringing these antibody applications to commercial markets. Biomira will receive option, licensing and milestone payments in addition to royalties from future sales of resulting products.
 Simultaneously with the signing of these agreements, Sterling Winthrop has exercised its option to license the previously developed Biomira 174 antibody for studies and potential use against squamous cell carcinomas of the cervix, lung, and head and neck. Joint research and development efforts by Sterling Winthrop and Biomira scientists are expected to accelerate the introduction of products based on this antibody to world markets.
 Biomira Inc. is a public biotechnology company focused on the research, development and commercialization of cancer diagnostic and therapeutic products. The firm, located in Edmonton Research Park, Edmonton, Alberta, Canada, currently markets four in vitro diagnostic kits for gastrointestinal, ovarian and breast cancers under the Truquant label. A number of its in vivo products are in various stages of clinical trials.
 Sterling Winthrop Inc. is a worldwide producer and marketer of pharmaceuticals and consumer health products. The discovery and development of anti-cancer agents is one of six primary areas of focus for Sterling Winthrop's Pharmaceuticals Research Division.
 -0- 2/10/92
 /CONTACT: Terry G. Kelley, 212-907-3009, or Diane C. Iselin, 212-907-2341, both of Sterling Winthrop Inc./ CO: Sterling Winthrop Inc.; Biomira Inc. ST: New York, Alberta IN: MTC SU: LIC


KD-KW -- NY091 -- 8518 02/10/92 17:44 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:415
Previous Article:AT&T SAYS 'GUNG HAY FAT CHOY'
Next Article:OCEANEERING ANNOUNCES THIRD QUARTER RESULTS
Topics:


Related Articles
BIOMIRA REACHES AGREEMENT IN PRINCIPLE
BIOMIRA AND STERLING WINTHROP SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
BIOMIRA ANNOUNCES EXCLUSIVE WORLD RIGHTS TO PEPTIDE ANTIGEN COULD LEAD TO 'DESIGNER DRUGS' AGAINST COMMON CANCERS
NEORX TO GRANT LICENSE FOR RHENIUM CANCER THERAPY TO STERLING WINTHROP AS PART OF A $10 MILLION AGREEMENT
NEORX CORPORATION AND STERLING WINTHROP INC. SIGN LICENSE AGREEMENT FOR CANCER RADIOIMMUNOTHERAPY TECHNOLOGY
STERLING WINTHROP'S U.S. PHARMACEUTICALS UNIT, SANOFI WINTHROP PHARMACEUTICALS, AND MEDRAD, ANNOUNCE DEVELOPMENT AGREEMENT
STERLING WINTHROP INC. AND ADVANCED MAGNETICS, INC. ANNOUNCE MRI CONTRAST AGENT LICENSE AND MARKETING AGREEMENT
StressGen Appoints John Neefe, M.D. as Vice President, Clinical Research and Regulatory Affairs.
AltaRex Update - Legal Proceedings With Biomira.
AltaRex and Biomira Announce Settlement of Lawsuits.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters